- Home
- GATX vs LEGN Comparison
GATX vs LEGN Comparison
Compare GATX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GATX | LEGN |
|---|---|---|
| Founded | 1898 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GATX | LEGN |
|---|---|---|
| Price | $184.83 | $18.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $195.00 | $64.23 |
| AVG Volume (30 Days) | 148.5K | ★ 2.8M |
| Earning Date | 02-19-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 8.56 | N/A |
| Revenue | ★ $1,704,900,000.00 | $909,045,000.00 |
| Revenue This Year | $11.64 | $68.20 |
| Revenue Next Year | $14.97 | $47.77 |
| P/E Ratio | $21.42 | ★ N/A |
| Revenue Growth | 10.66 | ★ 74.75 |
| 52 Week Low | $139.44 | $18.99 |
| 52 Week High | $186.61 | $45.30 |
Technical Indicators
Market Signals| Indicator | GATX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 71.39 | 33.03 |
| Support Level | $175.34 | $20.21 |
| Resistance Level | $186.61 | $23.88 |
| Average True Range (ATR) | 3.32 | 1.30 |
| MACD | 0.56 | -0.21 |
| Stochastic Oscillator | 85.66 | 4.10 |
Price Performance
Historical ComparisonAbout GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.